Addition of TPGS to folate-conjugated polymer micelles for selective tumor targeting.
Folate-conjugated polymer micelles poly(D,L-lactide-co-glycolide)-poly(ethylene glycol)-folate (PLGA-PEG-FOL) was fabricated to encapsulate anticancer drug doxorubicin for targeting delivery to cancer cells with overexpression of folate receptors. To increase therapeutic effect, D-alpha-tocopheryl polyethylene glycol succinate (TPGS) was added during the micelles preparation. The physicochemical study showed that the mixed micelles of PLGA-PEG-FOL and TPGS formed a homogeneous population. The addition of TPGS did not result in much variation in the micellar size, surface charge, and drug encapsulation efficiency. The cellular uptake study showed that mixed micelles with TPGS had higher cellular uptake compared with the ones without TPGS to drug-resistant cancer cells. These mixed micelles also selectively increased the cytotoxicity of drug on cancer cells but exhibited minimal cytotoxic enhancement on normal fibroblasts. Furthermore, the accumulation of rhodamine study showed that the mixed micelles with TPGS increased the cellular uptake of drugs on Caco-2 cells. This indicates that TPGS in the mixed micelles may act as P-glycoprotein inhibitor to reduce drug efflux. This new formulation with TPGS may have dual functions of folate-mediated targeting and multidrug resistance inhibition and can be promising in improving the therapeutic efficacy of polymer micellar targeting delivery system.
Zhao
Haizheng
H
Department of Chemical and Biomolecular Engineering, National University of Singapore, 10 Kent Ridge Crescent, Singapore.
Yung
Lin Yue Lanry
LY
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000235:genetics / Q000378:metabolism; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects; D002352:Carrier Proteins / Q000235:genetics / Q000378:metabolism; D002460:Cell Line; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D004317:Doxorubicin / Q000008:administration & dosage* / Q000494:pharmacology; D016503:Drug Delivery Systems; D058973:Folate Receptors, GPI-Anchored; D005492:Folic Acid / Q000737:chemistry*; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D019344:Lactic Acid / Q000737:chemistry*; D008823:Micelles; D011092:Polyethylene Glycols / Q000737:chemistry; D011100:Polyglycolic Acid / Q000737:chemistry*; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011956:Receptors, Cell Surface / Q000235:genetics / Q000378:metabolism; D012235:Rhodamines; D014810:Vitamin E / Q000031:analogs & derivatives* / Q000737:chemistry
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000970:Antineoplastic Agents; D002352:Carrier Proteins; D058973:Folate Receptors, GPI-Anchored; D008823:Micelles; D011956:Receptors, Cell Surface; D012235:Rhodamines; D014810:Vitamin E; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; D011092:Polyethylene Glycols; D004317:Doxorubicin; D005492:Folic Acid; C014225:tocophersolan